Pharmaceutical Research and Manufacturers of America

Logo of the Pharmaceutical Research and Manufacturers of America.

Pharmaceutical Research and Manufacturers of America (PhRMA, pronounced /ˈfɑrmə/), founded in 1958, is a trade group representing companies in the pharmaceutical industry in the United States.[1] PhRMA's stated mission is advocacy for public policies that encourage the discovery of new medicines for patients by companies engaged in pharmaceutical and biopharmaceutical research. PhRMA's current CEO is John J. Castellani and its chairman is Robert J. Hugin.

Leadership

John J. Castellani, formerly head of the Business Roundtable, a U.S. advocacy and lobbying group, is president and CEO of PhRMA.[2] He succeededs Billy Tauzin, a former Republican congressman from Louisiana.[3][4] and continued until he stepped down in 2010.[5]

Programs

SMARxT Disposal is a joint program run by the U.S. Fish and Wildlife Service, the American Pharmacists Association, and PhRMA to encourage consumers to properly dispose of unused medicines to avoid harm to the environment.[6]

The Partnership for Prescription Assistance is a program by PhRMA and its member companies that connects patients in-need with information on low-cost and free prescription medication.[6]

See also

References

  1. The Editorial Board (November 27, 2015). "Turn the Volume Down on Drug Ads". New York Times. Retrieved November 27, 2015.
  2. whorunsgov.com
  3. Pharmaceutical group shifts tone with new pick for president, by N.C. Alzenman and Dan Eggen, The Washington Post, July 14, 2010
  4. Judy Sarasohn Special Interests: Tauzin to Head Drug Trade Group The Washington Post December 16, 2004; Page A35.
  5. Julian Pecquet. "PhRMA picks new president" The Hill July 14, 2010. Vol. 17 Issue 81 page 22.
  6. 1 2 "Patient Resources". Pharmaceutical Research and Manufacturers of America. Archived from the original on March 19, 2011. Retrieved April 6, 2011.

External links

This article is issued from Wikipedia - version of the Sunday, April 17, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.